Liminatus Pharma Inc Dossier
Qualitative Analysis
Business overview
Liminatus Pharma, Inc. (NASDAQ: LIMN) is a pre-clinical stage biopharmaceutical company focused on developing innovative, immune-modulating cancer therapies. The company's lead clinical candidate is IBA101, a humanized anti-CD47 monoclonal antibody designed as a next-generation immune checkpoint inhibitor to target advanced solid cancers, including non-small cell lung cancer (NSCLC). IBA101 is engineered to preferentially bind to immune cells rather than red blood cells and platelets, thereby avoiding the common side effect of hemolysis. Liminatus transitioned to the public market on April 30, 2025, following a business combination with Iris Acquisition Corp.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Establishment of a dedicated subsidiary named 'American BNB Strategy' to lead digital asset investment and management initiatives, targeting the acquisition and long-term holding of up to $500 million in BNB coin.
Expected impact: Aims to utilize blockchain-integrated financial strategies to optimize treasury management, support long-term cancer research initiatives, and enhance shareholder value.
Advancing the clinical development of IBA101, a humanized anti-CD47 monoclonal antibody designed to block the CD47/SIRPα signaling axis without inducing hemagglutination or hemolysis.
Expected impact: Establish safety and efficacy in advanced solid cancers, specifically lung cancer, as a monotherapy and in combination with PD-1/PD-L1 checkpoint inhibitors.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To expand Liminatus' oncology pipeline with advanced CAR-T and antibody-based therapies, including clinical-stage candidate IBC101 (CD19xCD22 bivalent CAR-T) and preclinical solid-tumor candidates INC101 and INC102.
Financial impact: All-stock transaction involving the issuance of 1.6 billion shares of Liminatus common stock at $0.20 per share, plus contingent value rights (CVRs) representing 20% of future net proceeds from strategic transactions involving the acquired assets.
Strategic Partnerships
Collaborating alongside InnocsAI to develop an early-detection diagnostic kit for pancreatic cancer, leveraging the CA19-9-combined INNOCS platform to pursue regulatory approvals in both the U.S. and South Korea.